
The results of the first Multicenter Selective Lymphadenectomy Trial (MSLT-1) seem to indicate that survival in patients with intermediate thickness melanoma and metastatic disease in the regional nodes can be improved if early lymph node dissection is performed when a positive sentinel node is identified.
